Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials
JournalAmerican Journal of Tropical Medicine and Hygiene
PublisherAmerican Society of Tropical Medicine and Hygiene
MetadataShow full item record
AbstractMinority communities have borne the brunt of COVID-19 disease in the United States. Nonwhites have contracted most of the SARS-CoV-2 infections; COVID-19 mortality rates for Black Americans are more than twice those for whites. Given this, studying the most effective ways to prevent and treat SARS-CoV-2 in these populations should be a research priority, particularly with respect to vaccine trials. Federal guidelines from the National Institutes of Health and Food and Drug Administration emphasize the need for inclusion of minority groups in these trials, but none of the publicly available SARS-CoV-2 vaccine trial protocols requires representative sampling of minorities. This piece emphasizes the importance of adequate inclusion of minority communities in SARS-CoV-2 vaccine trials, and the implications of this inclusion for SARS-CoV-2 vaccine distribution. © 2021 by The American Society of Tropical Medicine and Hygiene
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14481
- What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
- Authors: Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ
- Issue date: 2021 Feb
- Researchers Strive to Recruit Hard-Hit Minorities Into COVID-19 Vaccine Trials.
- Authors: Jaklevic MC
- Issue date: 2020 Sep 1
- COVID-19 vaccines in high-risk ethnic groups.
- Authors: D'Souza RS, Wolfe I
- Issue date: 2021 Apr 10
- SARS-CoV-2 reinfection and implications for vaccine development.
- Authors: Nainu F, Abidin RS, Bahar MA, Frediansyah A, Emran TB, Rabaan AA, Dhama K, Harapan H
- Issue date: 2020 Dec 1
- A promising inactivated whole-virion SARS-CoV-2 vaccine.
- Authors: Isakova-Sivak I, Rudenko L
- Issue date: 2021 Jan